Back to Results
First PageMeta Content
Morphinans / Phenols / Ethers / Euphoriants / Buprenorphine / Opioid dependence / Methadone / Opioid / Morphine / Chemistry / Organic chemistry / Alcohols


C-1 Probuphine for Maintenance Treatment of Opioid Dependence Titan Pharmaceuticals, Inc. FDA Advisory Committee
Add to Reading List

Open Document

File Size: 1,52 MB

Share Result on Facebook

Company

Two Dreams Clinical Efficacy Katherine Glassman / Opioid Dependence Titan Pharmaceuticals Inc. / Chief Development Officer Titan Pharmaceuticals Inc. / D. / /

Facility

University of Miami / Segal Institute / /

MedicalCondition

Chronic Neurobiological Disease / complex diseases / /

Organization

C-7 Probuphine Administration / FDA / US Department of Health and Human Services / Food and Drug Administration Center for Drug Evaluation / Segal Institute for Clinical Research / Demand Reduction Office / Medication / American Society of Addiction Medicine / Substance Abuse and Mental Health Services Administration / University of Miami / Miller School / CCRP PI / /

Person

Garry Neil / Marc Rubin / Katherine Glassman-Beebe / Need Andrea Barthwell / Safety Steve Chavoustie / /

Position

Assistant Professor / CEO / General / Deputy Director / Executive Chairman / Head / Executive VP / Ph. Executive VP / /

Technology

drug delivery / /

URL

http /

SocialTag